146 related articles for article (PubMed ID: 22213215)
21. Cell-free epstein-barr viral loads in childhood hodgkin lymphoma: a study from South India.
Sinha M; Rao CR; Shafiulla M; Appaji L; Bs AK; Sumati BG; Avinash T; Jayshree RS
Pediatr Hematol Oncol; 2013 Sep; 30(6):537-43. PubMed ID: 23756088
[TBL] [Abstract][Full Text] [Related]
22. [Sequential monitoring of plasma EBV-DNA level in a patient with EBV-positive Hodgkin lymphoma].
Uchida E; Honma R; Igarashi A; Kurata M; Imadome K; Omoto E; Miura O; Arai A
Rinsho Ketsueki; 2012 Jan; 53(1):87-91. PubMed ID: 22374530
[TBL] [Abstract][Full Text] [Related]
23. [Correlation between the kinetics of plasma EBV DNA levels and clinical response during treatment in patients with nasopharyngeal carcinoma].
Peng PJ; Zhao C; Liao H; Wang FQ; Zhang L
Ai Zheng; 2002 Aug; 21(8):817-22. PubMed ID: 12478884
[TBL] [Abstract][Full Text] [Related]
24. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
25. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
26. Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study.
Wei WI; Yuen AP; Ng RW; Ho WK; Kwong DL; Sham JS
Head Neck; 2004 Oct; 26(10):878-83. PubMed ID: 15390201
[TBL] [Abstract][Full Text] [Related]
27. Clinical role of circulating Epstein-Barr virus DNA as a tumor marker in lymphoepithelioma-like carcinoma of the lung.
Ngan RK; Yip TT; Cheng WW; Chan JK; Cho WC; Ma VW; Wan KK; Au JS; Law CK
Ann N Y Acad Sci; 2004 Jun; 1022():263-70. PubMed ID: 15251971
[TBL] [Abstract][Full Text] [Related]
28. Clinical applications of plasma Epstein-Barr virus DNA analysis and protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA.
Chan KC; Lo YM
Methods Mol Biol; 2006; 336():111-21. PubMed ID: 16916257
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
30. Serum/plasma viral DNA: mechanisms and diagnostic applications to nasopharyngeal and cervical carcinoma.
Mutirangura A
Ann N Y Acad Sci; 2001 Sep; 945():59-67. PubMed ID: 11708495
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus-associated peripheral T-cell and NK-cell proliferative disease/lymphoma: clinicopathologic, serologic, and molecular analysis.
Mitarnun W; Suwiwat S; Pradutkanchana J; Saechan V; Ishida T; Takao S; Mori A
Am J Hematol; 2002 May; 70(1):31-8. PubMed ID: 11994979
[TBL] [Abstract][Full Text] [Related]
32. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma.
Bonnet F; Jouvencel AC; Parrens M; Leon MJ; Cotto E; Garrigue I; Morlat P; Beylot J; Fleury H; Lafon ME
J Clin Virol; 2006 Aug; 36(4):258-63. PubMed ID: 16762591
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr viral load as a marker of lymphoma in AIDS patients.
Fan H; Kim SC; Chima CO; Israel BF; Lawless KM; Eagan PA; Elmore S; Moore DT; Schichman SA; Swinnen LJ; Gulley ML
J Med Virol; 2005 Jan; 75(1):59-69. PubMed ID: 15543571
[TBL] [Abstract][Full Text] [Related]
35. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
36. Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting.
Gulley ML; Fan H; Elmore SH
J Mol Diagn; 2006 Nov; 8(5):589-97. PubMed ID: 17065428
[TBL] [Abstract][Full Text] [Related]
37. Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non-Hodgkin lymphomas.
Machado AS; Da Silva Robaina MC; Magalhães De Rezende LM; Apa AG; Amoêdo ND; Bacchi CE; Klumb CE
Leuk Lymphoma; 2010 Jun; 51(6):1020-7. PubMed ID: 20470219
[TBL] [Abstract][Full Text] [Related]
38. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
[TBL] [Abstract][Full Text] [Related]
39. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
40. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
